Last 12 months
Inside the activity.
0 purchase rows · 279 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 31 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 111 |
| Feb 2026 | 0 | 11 |
| Mar 2026 | 0 | 106 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2022 Filed Aug 5, 2022 20:13 UTC |
Greenstreet YvonneDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 195 | $209.83 | $40,916.85 |
DisclosureSEC source: 0001735276-22-000063 · edgardoc.xml · nonDerivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,369 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:13 UTC |
Greenstreet YvonneDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 5,433 | $189.76 | $1,030,966.08 |
DisclosureSEC source: 0001735276-22-000063 · edgardoc.xml · nonDerivative · entry 4 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,564 F4 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:15 UTC |
Tanguler TolgaEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,754 | $210.00 | $368,340.00 |
DisclosureSEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,629 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:15 UTC |
Tanguler TolgaEVP, Chief Commercial Officer
|
GrantCommon Stock | 3,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,383 F1 · kind: On February 24, 2021, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC |
Poulton Jeffrey V.EVP, Chief Financial Officer
|
GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000066 · edgardoc.xml · nonDerivative · entry 3 Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,460 F3 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC |
Poulton Jeffrey V.EVP, Chief Financial Officer
|
GrantCommon Stock | 3,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000066 · edgardoc.xml · nonDerivative · entry 2 Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,351 F2 · kind: On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC |
Poulton Jeffrey V.EVP, Chief Financial Officer
|
GrantCommon Stock | 4,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000066 · edgardoc.xml · nonDerivative · entry 1 Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,653 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC |
Garg PushkalCMO & EVP Dev & Med Affairs
|
GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,503 F3 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC |
Garg PushkalCMO & EVP Dev & Med Affairs
|
GrantCommon Stock | 3,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,394 F2 · kind: On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:14 UTC |
Garg PushkalCMO & EVP Dev & Med Affairs
|
GrantCommon Stock | 4,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000065 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,710 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC |
Vaishnaw AkshayPresident
|
GrantCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 3 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,398 F3 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC |
Vaishnaw AkshayPresident
|
GrantCommon Stock | 4,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 2 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,539 F2 · kind: On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC |
Vaishnaw AkshayPresident
|
GrantCommon Stock | 5,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000064 · edgardoc.xml · nonDerivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,298 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC |
Greenstreet YvonneDirector · Chief Executive Officer
|
GrantCommon Stock | 3,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000063 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,997 F3 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSU) in connection with the 2020 year-end compensation review. One quarter of the PSU award vests upon the achievement of each of four specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and the first quarter of the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC |
Greenstreet YvonneDirector · Chief Executive Officer
|
GrantCommon Stock | 4,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000063 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,138 F2 · kind: On October 7, 2020, the reporting person was granted a one-time strategic performance-based stock unit (PSU) award. The People, Culture and Compensation Committee of the Board determined that the performance criterion was met and the PSU award vested as of August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:13 UTC |
Greenstreet YvonneDirector · Chief Executive Officer
|
GrantCommon Stock | 5,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000063 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,985 F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and the second one-third of the PSU award vested as of August 3, 2022. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:06 UTC |
Tanguler TolgaEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,754 | $150.00 | $263,100.00 |
DisclosureSEC source: 0001735276-22-000057 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,754 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC |
PYOTT DAVID E IDirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000055 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC |
BRANDICOURT OLIVIERDirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000054 · edgardoc.xml · derivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC |
HAMBURG MARGARET ADirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000053 · edgardoc.xml · derivative · entry 1 HAMBURG MARGARET A · CIK 0001266917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:06 UTC |
SCHULMAN AMY WDirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000051 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:07 UTC |
Reitan Colleen FDirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000052 · edgardoc.xml · derivative · entry 1 Reitan Colleen F · CIK 0001740730 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:06 UTC |
Ausiello Dennis ADirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000050 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:05 UTC |
Fanucci MarshaDirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000049 · edgardoc.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:05 UTC |
SHARP PHILLIP ADirector
|
GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000048 · edgardoc.xml · derivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · derivative · entry 12 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 175 | $178.60 | $31,255.00 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 11 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 825 | $177.58 | $146,503.50 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 10 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F9 · price: Sale prices ranged from $177.12 to $178.00. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 526 | $176.51 | $92,844.26 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F8 · price: Sale prices ranged from $176.04 to $176.88. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 90 | $174.33 | $15,689.70 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,526 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 642 | $173.06 | $111,104.52 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,616 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F7 · price: Sale prices ranged from $172.83 to $173.37. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 1,434 | $172.10 | $246,791.40 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,258 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F6 · price: Sale prices ranged from $171.75 to $172.73. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 1,235 | $171.16 | $211,382.60 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,692 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F5 · price: Sale prices ranged from $170.70 to $171.63. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 4,872 | $169.71 | $826,827.12 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,927 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F4 · price: Sale prices ranged from $169.32 to $170.28. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 4,948 | $168.95 | $835,964.60 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,799 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F3 · price: Sale prices ranged from $168.30 to $169.30. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
SaleCommon Stock | 253 | $166.04 | $42,008.12 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,747 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F2 · price: Sale prices ranged from $165.91 to $166.41. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
PAUL STEVEN MDirector
|
Exercise / conversionCommon Stock | 15,000 | $11.33 | $169,950.00 |
DisclosureSEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:08 UTC |
PYOTT DAVID E IDirector
|
GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000028 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:12 UTC |
Garg PushkalCMO & EVP Dev & Med Affairs
|
GrantStock Option (right to buy) · Derivative | 24,128 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000037 · edgardoc.xml · derivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,128 Underlying: Common Stock · 24,128 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 12,884 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:12 UTC |
Tanguler TolgaEVP, Chief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 18,413 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000036 · edgardoc.xml · derivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,413 Underlying: Common Stock · 18,413 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 9,833 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:12 UTC |
Poulton Jeffrey V.EVP, Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 18,413 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000035 · edgardoc.xml · derivative · entry 1 Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,413 Underlying: Common Stock · 18,413 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 9,833 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:11 UTC |
Vaishnaw AkshayPresident
|
GrantStock Option (right to buy) · Derivative | 29,842 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000034 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,842 Underlying: Common Stock · 29,842 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 15,936 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:10 UTC |
Greenstreet YvonneDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 31,747 | $0.00 Strike: $147.47 | $0.00 |
DisclosureSEC source: 0001735276-22-000033 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,747 Underlying: Common Stock · 31,747 shares Expires 2032-02-22 F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2021. The reporting person also received 50,858 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:10 UTC |
Fanucci MarshaDirector
|
GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000032 · edgardoc.xml · derivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:10 UTC |
Ausiello Dennis ADirector
|
GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000031 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:09 UTC |
HAMBURG MARGARET ADirector
|
GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000030 · edgardoc.xml · derivative · entry 1 HAMBURG MARGARET A · CIK 0001266917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:09 UTC |
SCHULMAN AMY WDirector
|
GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000029 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:04 UTC |
SHARP PHILLIP ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001735276-22-000014 · edgardoc.xml · derivative · entry 4 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 30,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:04 UTC |
SHARP PHILLIP ADirector
|
SaleCommon Stock | 30,000 | $150.00 | $4,500,000.00 |
DisclosureSEC source: 0001735276-22-000014 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 30,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:04 UTC |
SHARP PHILLIP ADirector
|
Exercise / conversionCommon Stock | 30,000 | $11.33 | $339,900.00 |
DisclosureSEC source: 0001735276-22-000014 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 30,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.